With this in mind, we point to the relative increase in SGLT1 vs SGLT2 inhibition with sotagliflozin resulting in a greater reduction in MI and stroke in SCORED [5] compared with the results of the meta-analysis of SGLT2is which failed to show a reduction in stroke [3] and a similar reduction as the GLP-1 RAs [4] but with a greater reduction in HHF. Here, SLC5A2 is linked to stroke disorder.